Clinical Trial: IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors

U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07441174) titled 'IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors' on Feb. 13.

Brief Summary: This is a multicenter, open-label, Phase Ib/II clinical study. The study includes Phase Ib-Dose Exploration Stage and Phase II - Efficacy Exploration and Determination Stage.

Study Start Date: Feb. 28

Study Type: INTERVENTIONAL

Condition: Solid Tumor Cancer PDAC

Intervention: DRUG: IN10018 in combination with RNK08954

Based on existing clinical data, the RP2D of IN10018 as monotherapy and in combination with chemotherapy, targeted therapy, and immunotherapy is 100 mg QD. ...